IN8bio chose glioblastoma, a difficult solid tumor, for a strategic reason: to de-risk their platform. By delivering the therapy directly to the brain post-surgery, they could bypass trafficking issues. This ensures that if the therapy fails, it's due to the mechanism itself, not because it didn't reach the target.

EG427 began by focusing narrowly on neurogenic bladder in spinal cord injury patients. This specific application proved the technology's potential, attracted investors, and enabled the company to later expand its pinpoint DNA medicine into a broader platform for neurological diseases.

To reduce risk, Nuago prioritizes cancers based on two criteria: high unmet medical need and the existence of clinically validated delivery methods for that specific tissue. This strategy separates their novel drug science from novel delivery science, allowing them to focus resources on proving their mechanism without inventing a delivery system.

Despite pancreatic cancer being notoriously difficult, Actuate prioritized it as a lead indication for strategic reasons. Strong preclinical data allowed the company to bypass later-line trials and move directly into a first-line setting, a 'leapfrog' maneuver that significantly accelerates the drug's overall development and regulatory path.

Glioblastoma evolves under therapeutic pressure, changing its expression and metabolism to resist treatment. Adaptin Bio's platform is designed to be adaptive, allowing them to switch therapeutic payloads (e.g., from APTN-101 to 102) as the tumor changes, effectively staying one step ahead.

Diakonos chose glioblastoma, the deadliest brain cancer, for its first trial. This counterintuitive strategy provided a faster data readout, powerful validation upon success, and a lower regulatory burden from the FDA—all critical advantages for an early-stage company.

Unlike conventional treatments, Nuago's therapy is more effective against highly aggressive, late-stage tumors. The very biological traits that define aggressiveness—loss of microRNAs and upregulation of survival genes—are the exact vulnerabilities Nuago's platform exploits, making the most dangerous cancers the most responsive to treatment.

Unconventionally, Infinitopes' first-in-human trial targets neoadjuvant patients (newly diagnosed, pre-surgery). This provides cleaner efficacy signals compared to trials in heavily pre-treated patients and enables unique analysis of resected tumors to prove the vaccine's mechanism, a key differentiator from competitors.

For solid tumors, the critical design hurdle for T-cell engagers is achieving selectivity. Most target antigens are also expressed at low levels on healthy cells, so molecules must be engineered to attack tumors with high antigen expression while sparing healthy tissue to avoid on-target, off-tumor toxicity.